The genomic landscape of matching primary and metastatic melanoma tumours uncovers relevant pathways for the metastatic process
Background: Metastatic melanoma treatment decisions are often made using the available tumour biopsy. The primary tumour is the most common specimen that is molecularly assessed to determine the mutation status, which guides patient therapy, but this is limited due to interpatient and intermetastatic tumour heterogeneity.
Authors
- Lisa N. Tom (ORCID: https://orcid.org/0000-0002-9068-1107)
- Ariane Aigelsreiter (ORCID: https://orcid.org/0000-0002-9835-6982)
- Erika Richtig (ORCID: https://orcid.org/0000-0002-5505-6103)
- Darren J. Smit (ORCID: https://orcid.org/0000-0002-3288-3659)
- H. Peter Soyer (ORCID: https://orcid.org/0000-0002-4770-561X)
- Yeh‐Chih Kao
- Thomas M. Harris (ORCID: https://orcid.org/0000-0002-3062-344X)
- Georg Richtig (ORCID: https://orcid.org/0000-0002-4437-4413)
- Kasturee Jagirdar (ORCID: https://orcid.org/0000-0001-8761-132X)
- Harald Oey
- Mitchell Stark (ORCID: https://orcid.org/0000-0002-4510-2161)
Institutions
- The University of Queensland (AU)
- Medical University of Graz (AT)
Publication Details
- Journal
- EJC Skin Cancer
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.ejcskn.2025.100504
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00